
|Videos|March 17, 2022
Dr. Shore encourages clinicians to implement hereditary cancer risk assessments in their practices
Author(s)Urology Times staff
“The take-home message is that it's not a question of if you're going to start doing a hereditary cancer risk assessment, it's when,” says Neal D. Shore, MD, FACS.
Advertisement
In this video, Neal D. Shore, MD, FACS, discusses the takeaways of the study, “Hereditary cancer risk assessment in the community urology practice setting,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












